帕博利珠单抗治疗伴有 PD-L1 结构变异的蕈样肉芽肿。
Pembrolizumab in mycosis fungoides with PD-L1 structural variants.
机构信息
Division of Medical Oncology, Department of Medicine.
Department of Pathology, and.
出版信息
Blood Adv. 2021 Feb 9;5(3):771-774. doi: 10.1182/bloodadvances.2020002371.
Abstract
PD-L1 structural variants are recurrent in mycosis fungoides with large cell transformation. PD-L1 structural variants in relapsed/refractory mycosis fungoides should prompt consideration of treatment with PD-1 inhibitors.
摘要
PD-L1 结构变异在大细胞转化蕈样肉芽肿中频繁发生。复发性/难治性蕈样肉芽肿中存在 PD-L1 结构变异时，应考虑使用 PD-1 抑制剂进行治疗。
相似文献
1
Pembrolizumab in mycosis fungoides with PD-L1 structural variants.帕博利珠单抗治疗伴有 PD-L1 结构变异的蕈样肉芽肿。
Blood Adv. 2021 Feb 9;5(3):771-774. doi: 10.1182/bloodadvances.2020002371.
2
Clinical Response in Heavily Pretreated Mycosis Fungoides with Pembrolizumab: A Case Report.帕博利珠单抗治疗广泛预处理蕈样肉芽肿的临床反应：一例报告。
Acta Haematol. 2022;145(2):207-209. doi: 10.1159/000518815. Epub 2021 Oct 13.
3
Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides.帕博利珠单抗和来那度胺治疗晚期难治性蕈样肉芽肿的疗效
Leuk Lymphoma. 2019 Apr;60(4):1079-1082. doi: 10.1080/10428194.2018.1516879. Epub 2018 Oct 10.
4
Successful treatment of relapsed folliculotropic mycosis fungoides with mogamulizumab followed by intensity-modulated radiotherapy.用莫加莫拉单抗治疗复发性毛囊性蕈样肉芽肿，随后进行调强放疗取得成功。
J Dermatol. 2018 Apr;45(4):e84-e85. doi: 10.1111/1346-8138.14111. Epub 2017 Oct 25.
5
Dupilumab, Atopic Dermatitis, and Mycosis Fungoides-New Insights on an Evolving Story.度普利尤单抗、特应性皮炎和蕈样肉芽肿——一个不断发展的故事的新见解。
JAMA Dermatol. 2023 Nov 1;159(11):1177-1178. doi: 10.1001/jamadermatol.2023.3846.
6
A case of mycosis fungoides successfully treated with combination of bexarotene and mogamulizumab.一例蕈样肉芽肿采用贝沙罗汀和莫加莫单抗联合治疗成功治愈。
Dermatol Ther. 2021 Mar;34(2):e14805. doi: 10.1111/dth.14805. Epub 2021 Jan 27.
7
Alemtuzumab induced complete remission of romidepsin-refractory large cell transformation of mycosis fungoides.阿仑单抗诱导难治性罗米地辛蕈样肉芽肿大细胞转化完全缓解。
Ann Hematol. 2014 Apr;93(4):713-4. doi: 10.1007/s00277-013-1869-z. Epub 2013 Aug 11.
8
Progression of mycosis fungoides after treatment with dupilumab: A case report.使用度普利尤单抗治疗后蕈样肉芽肿的进展：一例报告。
Dermatol Ther. 2020 Nov;33(6):e13880. doi: 10.1111/dth.13880. Epub 2020 Jul 12.
9
Mycosis Fungoides Unmasked by Dupilumab Treatment in a Patient With a History of Atopic Dermatitis.度普利尤单抗治疗一名有特应性皮炎病史患者后暴发性蕈样肉芽肿
Dermatitis. 2021 Oct 1;32(1S):e88-e89. doi: 10.1097/DER.0000000000000679.
10
Bone granulomatous infiltrate associated with mogamulizumab in a patient with mycosis fungoides.蕈样肉芽肿患者中与莫加莫珠单抗相关的骨肉芽肿浸润。
Lancet Haematol. 2023 Feb;10(2):e155. doi: 10.1016/S2352-3026(22)00354-4.
引用本文的文献
1
Mycosis Fungoides, Sézary Syndrome, and Cutaneous B-Cell Lymphomas: 2025 Update on Diagnosis, Risk-Stratification, and Management.蕈样肉芽肿、塞扎里综合征和皮肤B细胞淋巴瘤：2025年诊断、风险分层及管理的最新进展
Am J Hematol. 2025 Sep;100(9):1603-1628. doi: 10.1002/ajh.27735. Epub 2025 Jun 10.
2
Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL).皮肤T细胞淋巴瘤（CTCL）新型全身治疗方法的进展
Curr Hematol Malig Rep. 2025 Jan 13;20(1):5. doi: 10.1007/s11899-024-00746-7.
3
Differential Upregulation of Th1/Th17-Associated Proteins and PD-L1 in Granulomatous Mycosis Fungoides.肉芽肿性蕈样霉菌病中Th1/Th17相关蛋白和PD-L1的差异上调
Cells. 2024 Feb 27;13(5):419. doi: 10.3390/cells13050419.
4
Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments.蕈样肉芽肿和赛泽里综合征治疗进展：皮肤靶向治疗和免疫治疗的叙述性更新。
Front Immunol. 2023 Oct 5;14:1284045. doi: 10.3389/fimmu.2023.1284045. eCollection 2023.
5
Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma.皮肤T细胞淋巴瘤治疗中免疫疗法的进展
Cancer Manag Res. 2023 Sep 6;15:989-998. doi: 10.2147/CMAR.S330908. eCollection 2023.
6
The evolving role of reduced-dose total skin electron beam therapy in skin malignancies: the renaissance of a rare indication.低剂量全身电子束放射治疗在皮肤恶性肿瘤中的作用演变：罕见适应证的复兴。
Strahlenther Onkol. 2023 Oct;199(10):950-953. doi: 10.1007/s00066-023-02115-4. Epub 2023 Jul 14.
7
Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma.复发难治性外周T细胞淋巴瘤的治疗进展
Cancers (Basel). 2023 Jan 18;15(3):589. doi: 10.3390/cancers15030589.
8
Harnessing the immune system in the treatment of cutaneous T cell lymphomas.利用免疫系统治疗皮肤T细胞淋巴瘤。
Front Oncol. 2023 Jan 12;12:1071171. doi: 10.3389/fonc.2022.1071171. eCollection 2022.
9
Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations.泛癌种程序性死亡配体-1 和程序性死亡配体-2 结构变异全景。
JCO Precis Oncol. 2023 Jan;7:e2200300. doi: 10.1200/PO.22.00300.
10
Moving towards biologically informed treatment strategies for T-cell lymphomas.朝着针对 T 细胞淋巴瘤的生物学导向治疗策略迈进。
Int J Hematol. 2023 Apr;117(4):492-503. doi: 10.1007/s12185-022-03524-4. Epub 2022 Dec 27.
本文引用的文献
1
The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.肿瘤突变负荷对癌症中免疫检查点抑制剂疗效的预测价值：一项系统评价和荟萃分析
Front Oncol. 2019 Nov 5;9:1161. doi: 10.3389/fonc.2019.01161. eCollection 2019.
2
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.派姆单抗治疗复发/难治性蕈样霉菌病和塞扎里综合征：一项多中心 II 期研究。
J Clin Oncol. 2020 Jan 1;38(1):20-28. doi: 10.1200/JCO.19.01056. Epub 2019 Sep 18.
3
Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.EB 病毒相关淋巴瘤中频繁涉及程序性死亡配体的结构变异。
Leukemia. 2019 Jul;33(7):1687-1699. doi: 10.1038/s41375-019-0380-5. Epub 2019 Jan 25.
4
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.莫格利珠单抗对比伏立诺他治疗既往治疗的皮肤 T 细胞淋巴瘤（MAVORIC）：一项国际性、开放性标签、随机、对照的 3 期临床试验。
Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9.
5
An Integrated Data Resource for Genomic Analysis of Cutaneous T-Cell Lymphoma.皮肤T细胞淋巴瘤基因组分析的综合数据资源
J Invest Dermatol. 2018 Dec;138(12):2681-2683. doi: 10.1016/j.jid.2018.06.176. Epub 2018 Jul 5.
6
Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E).对220例皮肤T细胞淋巴瘤（CTCL）进行的基因组分析确定了RLTPR（p.Q575E）中一种新的复发性功能获得性改变。
Blood. 2017 Sep 21;130(12):1430-1440. doi: 10.1182/blood-2017-02-768234. Epub 2017 Jul 10.
7
Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.多种癌症中通过 3'-UTR 破坏导致的异常 PD-L1 表达。
Nature. 2016 Jun 16;534(7607):402-6. doi: 10.1038/nature18294. Epub 2016 May 23.
8
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.纳武利尤单抗治疗复发或难治性血液系统恶性肿瘤患者：Ib期研究的初步结果
J Clin Oncol. 2016 Aug 10;34(23):2698-704. doi: 10.1200/JCO.2015.65.9789. Epub 2016 Jun 6.
9
Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.覃样肉芽肿的基因组分析确定关键T细胞信号传导和分化基因的改变。
Nat Genet. 2015 Dec;47(12):1426-34. doi: 10.1038/ng.3444. Epub 2015 Nov 9.
10
The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.皮肤T细胞淋巴瘤和蕈样肉芽肿综合征的突变图谱。
Nat Genet. 2015 Dec;47(12):1465-70. doi: 10.1038/ng.3442. Epub 2015 Nov 9.
Zotero 插件